Originally published in 2009, used to stratify clinical risk for stroke and thromboembolism in patients with atrial fibrillation based on a risk factor approach
Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263-272. doi:10.1378/chest.09-1584
See: https://www.ncbi.nlm.nih.gov/pubmed/19762550
Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33(12):1500-1510. doi:10.1093/eurheartj/ehr488
See: https://www.ncbi.nlm.nih.gov/pubmed/22246443
Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association [published correction appears in Eur Heart J. 2013 Mar;34(10):790] [published correction appears in Eur Heart J. 2013 Sep;34(36):2850-1]. Eur Heart J. 2012;33(21):2719-2747. doi:10.1093/eurheartj/ehs253
See: https://www.ncbi.nlm.nih.gov/pubmed/22922413
Ntaios G, Lip GY, Makaritsis K, et al. CHADS₂, CHA₂S₂DS₂-VASc, and long-term stroke outcome in patients without atrial fibrillation. Neurology. 2013;80(11):1009-1017. doi:10.1212/WNL.0b013e318287281b
See: https://www.ncbi.nlm.nih.gov/pubmed/23408865
Okumura K, Inoue H, Atarashi H, et al. Validation of CHA₂DS₂-VASc and HAS-BLED scores in Japanese patients with nonvalvular atrial fibrillation: an analysis of the J-RHYTHM Registry. Circ J. 2014;78(7):1593-1599. doi:10.1253/circj.cj-14-0144
See: https://www.ncbi.nlm.nih.gov/pubmed/24759791